

Ref: FOI/GS/ID 8113

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

17 April 2023

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Nivolumab.

You asked:

Q1. In the last 3 months, how many patients have been initiated on the following agents for the treatment of melanoma?*

- a. Ipilimumab (monotherapy)*
- b. Nivolumab (monotherapy)*
- c. Nivolumab AND Ipilimumab (combination)*
- d. Pembrolizumab*
- e. Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)*
- f. Other active systemic anti-cancer therapy*

**Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

Q2. In the last 3 months, how many patients have been initiated on the following agents for the treatment of Renal Cell Carcinoma?*

- a. Nivolumab (monotherapy)*
- b. Nivolumab + Ipilimumab*
- c. Nivolumab + Cabozantinib*
- d. Avelumab + Axitinib*

**Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

Q3. In the past 3 months, how many patients have been initiated on the following agents for treatment of Oesophageal Cancer:*

- a. Nivolumab monotherapy or in combination with Ipilimumab*
- b. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)*

c. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)

**Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

Trust response:

Answers below for the period 1/1/2023-31/3/2023.

1.

- a. 1
- b. 0
- c. 5
- d. 12
- e. 3
- f. 1

2.

- a. 0
- b. 0
- c. 0
- d. 3

3.

- a. 0
- b. 0
- c. 2